Literature DB >> 14991277

[Rheumatologic treatment in the G-DRG system].

N Roeder1, W Fiori, J L Hülsemann, N Könecke, H Lehmann, W Liman, H-J Lakomek.   

Abstract

On June 27 2000, the German Self-Administration and lately the German Ministry of Health set the general conditions for a new reimbursement system for the inpatient hospital sector which is based nearly exclusively on lump-sum payments. The Association of Acute Rheumatology Hospitals (VRA) and the DRG-Research-Group, Münster University Hospital, conducted a multi-center trial which included 7266 cases from 22 different hospitals. The data were used to analyze how well the not yet German healthcare adjusted G-DRG system (version 1.0) accounts for rheumatologic diagnostics and treatment as well as problems of specialized hospitals. 7 Adjacent-DRGs covered 91% of all cases, 68% of all cases were grouped into only two different Adjacent-DRGs (169 Bone Diseases and Specific Arthropathies and 166 Other Connective Tissue Disorders). Groups with different complexity which are not appropriately covered by the existing G-DRG system could be identified. The data further revealed a systematically longer length of stay in rheumatology clinics opposed to the average length of stay in the data used for calculating the G-DRGs, due to different structures and procedures of the complex rheumatologic treatment. The results strongly supported the assumption that an accurate reimbursement of rheumatologic cases in the current G-DRG system 1.0 would not have been possible. Adaptations made in the new G-DRG Version 2004 can only partly solve these problems, despite an improved construction of the DRGs. In order to guarantee an appropriate reimbursement of rheumatology clinics from 2005 on, the G-DRG system must be adapted to specific rheumatological pathways and/or alternative or additional reimbursement systems have to be found.

Entities:  

Mesh:

Year:  2004        PMID: 14991277     DOI: 10.1007/s00393-004-0578-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  5 in total

1.  [The multimodal rheumatologic complex treatment (OPS 8-983)--challenges, solutions and perspectives].

Authors:  H-J Lakomek; W Fiori; K Buscham; J L Hülsemann; N Köneke; W Liman; E Märker-Hermann; N Roeder
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

2.  [What changes for rheumatologists in the G-DRG system 2006?].

Authors:  A Liedtke-Dyong; W Fiori; H-J Lakomek; J L Hülsemann; N Köneke; W Liman; N Roeder
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

3.  [Increasingly appropriate depiction of rheumatology for G-DRG reimbursement 2006].

Authors:  H J Lakomek; W Fiori; K Buscham; J Hülsemann; N Köneke; W Liman; E Märker-Hermann; N Roeder
Journal:  Z Rheumatol       Date:  2006-02       Impact factor: 1.372

4.  [Changes for the field of rheumatology in the G-DRG-System 2007].

Authors:  A Liedtke-Dyong; W Fiori; H-J Lakomek; A Wenke; W Liman; N Roeder
Journal:  Z Rheumatol       Date:  2007-07       Impact factor: 1.372

Review 5.  [Structures of acute rheumatic care].

Authors:  M Stier-Jarmer; W Liman; G Stucki; J Braun
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.